Replimune Group (REPL) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.54
- Estimate
- -$0.79
- Surprise
- +31.5%
- Score today
- 4.6/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Replimune Group (REPL) reported a narrower loss than forecast — adjusted EPS of -$0.54 against the -$0.79 estimate (a 31.5% beat on a still-unprofitable quarter).
Coverage in the report window
- Leerink Partners Maintains Outperform Rating and Raises Price Target for Replimune Group — fiscal.ai, 2026-10-30
- JP Morgan Raises Replimune Group, Inc. Price Target to $27 — fiscal.ai, 2026-10-30
- Leerink Partners Maintains Outperform on Replimune Group, Raises Price Target to $31 — benzinga, 2026-10-29
Where TrendMatrix's rating stands now
TrendMatrix currently rates REPL Sell at 4.6/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's +31.5% surprise compares with a +10.7% four-quarter average. Next scheduled report: 2027-02-03.
What argues against it
- Concentration risk — Pipeline: RPx platform
- Concentration risk — Supplier: BMS nivolumab supply
- Quality below floor (1.6 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $19.88
- Price target
- $22.18
- Stop
- $18.49
- Upside to target
- +11.6%
- Reward-to-risk
- 0.8:1
Model outputs from TrendMatrix’s engine as of 2026-11-17 — shown for context, not personalized investment advice.
REPL at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $2.03B
- P/E (fwd)
- -31.9
- 52-week range
- $1.50–$23.54
- Off 52-week high
- 15.5%
- RSI (14)
- 65
- Volume vs avg
- 0.39×
- Score today
- 4.6/10